GlaxoSmithKline Says Salford Lung Study Has Positive Results
May 24 2016 - 6:42AM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK.LN) Tuesday said the Salford
lung study for chronic obstructive pulmonary disease, in
collaboration with Innoviva Inc. (INVA), has had positive headline
results.
The FTSE-100 healthcare company said the study showed that
Relvar Ellipta achieved a superior reduction in exacerbations,
compared with the usual care, in patients with COPD in an everyday
clinical-practice setting. Study analyses are ongoing, the company
said.
Shares at 1000 GMT up 5.50 pence, or 0.4%, at 1443.50 pence
valuing the company at 70.32 billion pounds ($101.94 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
May 24, 2016 06:27 ET (10:27 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024